Hypogonadism Completed Phase 3 Trials for Testosterone (DB00624)

IndicationStatusPhase
DBCOND0009256 (Hypogonadism)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02847806Effects of Replacement Therapy With Sexual Steroid Hormones on the Insulin Sensitivity of Hypogonadal ManTreatment
NCT02722278A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal MenBasic Science
NCT00345969Exercise and Testosterone Therapy in Elderly Men With Physical FrailtyTreatment
NCT02159469Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With HypogonadismTreatment
NCT00467870Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal MenTreatment
NCT00522431A Study of Fortigel Testosterone Gel 2% in Males With Low TestosteroneTreatment
NCT02514629Testosterone, Metformin, or Both, for Hypogonadism in Obese MalesTreatment
NCT00244023Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors AloneTreatment
NCT00433199Testosterone Treatment for Hypogonadal MenTreatment
NCT00702650A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) FormulationsTreatment
NCT00857454A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion FormulationsTreatment
NCT01816295A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and EnergyTreatment
NCT02504541Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism (STEADY)Treatment